Charles W. Chapman

A novel, orally active LPA ₁ receptor antagonist inhibits lung fibrosis in the mouse bleomycin model

J. S. Swaney, Charles W. Chapman, LD Correa et al. · British Journal of Pharmacology · 2010 · 257 citations · Full text

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

J. S. Swaney, Charles W. Chapman, Lucia Correa et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 126 citations

5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3- <i>tert</i> -Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1 <i>H</i> -indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor

Nicholas Stock, Gretchen Bain, Jasmine Zunic et al. · Journal of Medicinal Chemistry · 2011 · 47 citations · Full text

5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3-<i>tert</i>-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1<i>H</i>-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103)

John H. Hutchinson, Yiwei Li, Jeannie M. Arruda et al. · Journal of Medicinal Chemistry · 2009 · 41 citations · Full text

Total Syntheses and Biological Evaluation of Both Enantiomers of Several Hydroxylated Dimeric Nuphar Alkaloids

Alexander Korotkov, Hui Li, Charles W. Chapman et al. · Angewandte Chemie International Edition · 2015 · 25 citations · Full text